A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
Status:
Completed
Trial end date:
2020-08-12
Target enrollment:
Participant gender:
Summary
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to
evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808; an
oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with
acromegaly that are responders to octreotide LAR or lanreotide depot.